Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ABM-1310 / ABM Therap
NCT04190628: Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors	Terminated	1	53	US	ABM-1310, ABM1310, Cobimetinib, Cotellic®	ABM Therapeutics Corporation	Advanced Solid Tumor, BRAF V600 Mutation	04/24	04/24
NCT05501912: A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors	Terminated	1	20	RoW	ABM-1310	ABM Therapeutics Shanghai Company Limited	Advanced Solid Tumor, BRAF V600 Mutation	06/24	06/24
NCT05892653: A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors	Terminated	1	15	RoW	ABM-1310	ABM Therapeutics Shanghai Company Limited	Primary Malignant Brain Tumor	08/24	08/24
ABM-168 / ABM Therap
NCT05831995: Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.	Terminated	1	12	US	ABM-168	ABM Therapeutics Corporation	Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation	06/24	06/24
ABM-2624 / ABM Therap
No trials found
ABM-2697 / ABM Therap
No trials found
ABM-2752 / ABM Therap
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ABM-1310 / ABM Therap
NCT04190628: Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors	Terminated	1	53	US	ABM-1310, ABM1310, Cobimetinib, Cotellic®	ABM Therapeutics Corporation	Advanced Solid Tumor, BRAF V600 Mutation	04/24	04/24
NCT05501912: A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors	Terminated	1	20	RoW	ABM-1310	ABM Therapeutics Shanghai Company Limited	Advanced Solid Tumor, BRAF V600 Mutation	06/24	06/24
NCT05892653: A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors	Terminated	1	15	RoW	ABM-1310	ABM Therapeutics Shanghai Company Limited	Primary Malignant Brain Tumor	08/24	08/24
ABM-168 / ABM Therap
NCT05831995: Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.	Terminated	1	12	US	ABM-168	ABM Therapeutics Corporation	Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation	06/24	06/24
ABM-2624 / ABM Therap
No trials found
ABM-2697 / ABM Therap
No trials found
ABM-2752 / ABM Therap
No trials found